Andrew W. Adams (HC) is a Co-Founder and Managing Partner of Oak HC/FT where he focuses on growth equity and early-stage venture opportunities in Healthcare.

Andrew currently serves on the Boards of AllyAlign Health, August Bioservices, DispatchHealth, Eating Recovery Center, Everside Health, Galileo, Infusion for Health, Reveleer, Rialtic, Unified Women's Healthcare, US HealthVest, Veda and WithMe Health. Andrew is also actively involved with Noom, Precision Medicine Group and Sema4 (NASDAQ: SMFR).

Recent prior investments include Core Informatics (acquired by Thermo Fischer Scientific), LDI (acquired by Diplomat Pharmacy), Limeade (ASX: LME), Maestro Health (acquired by AXA Group), One Medical Group (NASDAQ:ONEM) and Therapy Brands (acquired by KKR). Other prior investments include American Esoteric Laboratories (acquired by Sonic Healthcare Limited), Argus Information & Advisory Services (acquired by Verisk Analytics), Benefitfocus (NASDAQ: BNFT), CareMedic Systems (acquired by Ingenix), CLARiENT (acquired by GE Healthcare), Health Dialog (acquired by British United Provident Association), iHealth Technologies (merged with Connolly), Independent Living Systems, NetSpend Corporation (acquired by TSYS), PayFlex Systems (acquired by Aetna), PharMEDium Healthcare (acquired by CD&R) and United BioSource (acquired by Medco Health Solutions).

Andrew joined Oak Investment Partners in 2003 and prior to that was a Senior Associate with Capital Resource Partners, a mezzanine capital firm where he focused on investments in healthcare and business services companies. Andrew was also a Financial Analyst in the media and communications group of Deutsche Banc Alex. Brown.

Andrew received a Bachelor of Arts degree from Princeton University.